Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation

Introduction: secondary hyperparathyroidism (SHP) is frequent in patients with chronic kidney disease (CKD), particularly in those in dialysis. To treat this complication, the current options available include phosphorus restriction, phosphate binders, the inhibition of parathyroid hormone (PTH) syn...

Full description

Autores:

D’Marco, Luis
Checa-Ros, Ana
Gamero, Dionilux
Soto, Carlos
Salazar, Juan
Nava, Manuel
Bermúdez, Valmore
Dapana, Fabiola

Tipo de recurso:

Fecha de publicación:

2022

Institución:

Universidad Simón Bolívar

Repositorio:

Repositorio Digital USB

Idioma:

eng

OAI Identifier:

oai:bonga.unisimon.edu.co:20.500.12442/13230

Acceso en línea:

https://hdl.handle.net/20.500.12442/13230
https://doi.org/10.3390/healthcare11010072

Palabra clave:

calcimimetics; vitamin D analogs; chronic kidney disease; inflammation

Rights

openAccess

License

Attribution-NonCommercial-NoDerivatives 4.0 Internacional